 |
|
|
| |
Characterization of Changes in FibroTest Values During
Treatment With TAF or TDF in Patients With CHB
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Namiki Izumi, 1 Owen Tak Yin Tsang, 2 Sang Hoon Ahn, 3 Selim Gurel, 4 Peter W. Angus, 5 John F. Flaherty, 6 Kyungpil Kim, 6 Anuj Gaggar, 6 Vithika Suri, 6 G. Mani Subramanian, 6 Curtis Cooper, 7 Hie-Won Hann, 8 Subrat K. Acharya 9
1Japanese Red Cross Musashino Hospital, Tokyo, Japan; 2Princess Margaret Hospital, Hong Kong; 3Yonsei University College of Medicine, Seoul, Korea; 4Uludag University, Bursa, Turkey; 5Austin Medical Research Foundation, Heidelberg, Victoria, Australia;
6Gilead Sciences, Inc., Foster City, CA; 7Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 8Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA; 9All India Institute of Medical Sciences, New Delhi, India
References
1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Sax P, et al. Lancet 2015;385:2606-15; 6. Mills A, et al. Lancet Infect Dis 2016;16:43-52; 7. Salkic NN, et al. Am J Gastroenterol 2014;109:796-809; 8. Terrault NA, et al. Hepatology 2016;63:261-83; 9. Behrens G, et al. Antiviral Ther 2012;17:1011-20.
|
| |
|
|
|
|
|
